Hepion Pharmaceuticals Stock Today
| HEPA Stock | USD 1.52 0.16 11.76% |
Performance2 of 100
| Odds Of DistressOver 67
|
Hepion Pharmaceuticals is trading at 1.52 as of the 3rd of May 2024, a 11.76 percent increase since the beginning of the trading day. The stock's open price was 1.36. Hepion Pharmaceuticals has more than 67 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Hepion Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of April 2024 and ending today, the 3rd of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of February 2014 | Category Healthcare | Classification Health Care |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. The company has 5.47 M outstanding shares of which 63.97 K shares are currently shorted by private and institutional investors with about 2.0 trading days to cover. More on Hepion Pharmaceuticals
Moving against Hepion Stock
| 0.56 | PDEX | Pro Dex | PairCorr |
| 0.51 | DXR | Daxor | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 10th of May 2024
Hepion Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hepion Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hepion Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO, Director | Robert Foster | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Hepion Pharmaceuticals report their recommendations after researching Hepion Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Hepion Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Hepion Pharmaceuticals. The Hepion consensus assessment is calculated by taking the average forecast from all of the analysts covering Hepion Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Hepion Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Hepion Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. Financial strength of Hepion Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Hepion Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Hepion Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hepion Pharmaceuticals' financial leverage. It provides some insight into what part of Hepion Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Hepion Pharmaceuticals (HEPA) is traded on NASDAQ Exchange in USA. It is located in 399 Thornall Street, Edison, NJ, United States, 08837 and employs 22 people. Hepion Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hepion Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Hepion Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hepion Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 5.47 M outstanding shares of which 63.97 K shares are currently shorted by private and institutional investors with about 2.0 trading days to cover.
Hepion Pharmaceuticals currently holds about 59.15 M in cash with (40.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78.
Check Hepion Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationHepion Pharmaceuticals secures a total of 5.47 Million outstanding shares. Roughly 86.0 (percent) of Hepion Pharmaceuticals outstanding shares are held by general public with 0.3 % owned by insiders and only 13.66 pct. by outside corporations. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Hepion Ownership Details
Hepion Stock Price Odds Analysis
What are Hepion Pharmaceuticals' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Hepion Pharmaceuticals jumping above the current price in 90 days from now is about 90.88%. The Hepion Pharmaceuticals probability density function shows the probability of Hepion Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Hepion Pharmaceuticals has a beta of 0.7179. This usually indicates as returns on the market go up, Hepion Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Hepion Pharmaceuticals will be expected to be much smaller as well. Additionally, hepion Pharmaceuticals has an alpha of 0.0695, implying that it can generate a 0.0695 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Hepion Pharmaceuticals to move above the current price in 90 days from now is about 90.88 (This Hepion Pharmaceuticals probability density function shows the probability of Hepion Stock to fall within a particular range of prices over 90 days) .
Hepion Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Hepion Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Hepion Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Hepion Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Jpmorgan Chase & Co | 2023-12-31 | 1.1 K | |
| Group One Trading, Lp | 2023-12-31 | 339 | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 114 | |
| Bank Of America Corp | 2023-12-31 | 114 | |
| Wells Fargo & Co | 2023-12-31 | 33.0 | |
| Royal Bank Of Canada | 2023-12-31 | 20.0 | |
| Barclays Plc | 2023-12-31 | 16.0 | |
| Ubs Group Ag | 2023-12-31 | 2.0 | |
| Signaturefd, Llc | 2023-12-31 | 1.0 | |
| Armistice Capital, Llc | 2023-12-31 | 418 K | |
| Vanguard Group Inc | 2023-12-31 | 160.3 K |
Hepion Pharmaceuticals Historical Income Statement
Hepion Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Hepion's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Hepion Pharmaceuticals revenue and expense. Hepion Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Hepion Pharmaceuticals' Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 47.5 M, whereas Selling General Administrative is forecasted to decline to 9,137. View More FundamentalsHepion Stock Against Markets
Picking the right benchmark for Hepion Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Hepion Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Hepion Pharmaceuticals is critical whether you are bullish or bearish towards Hepion Pharmaceuticals at a given time. Please also check how Hepion Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hepion Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
| All Next | Launch Module |
Hepion Pharmaceuticals Corporate Directors
Hepion Pharmaceuticals corporate directors refer to members of a Hepion Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Hepion Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Hepion Pharmaceuticals' board members must vote for the resolution. The Hepion Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Thomas Adams | Independent Director | Profile | |
| Timothy Block | Independent Director | Profile | |
| John Brancaccio | Independent Director | Profile | |
| Arnold Lippa | Independent Director | Profile |
How to buy Hepion Stock?
Before investing in Hepion Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Hepion Pharmaceuticals. To buy Hepion Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Hepion Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Hepion Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Hepion Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Hepion Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Hepion Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Hepion Stock please use our How to Invest in Hepion Pharmaceuticals guide.
Already Invested in Hepion Pharmaceuticals?
The danger of trading Hepion Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Hepion Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Hepion Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Hepion Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Hepion Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.32) | Return On Assets (0.72) | Return On Equity (1.71) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.